NewAmsterdam Pharma Company N.V.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael H. Davidson
- Full Time Employees
- 100
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Gooimeer 2-35 Naarden NH Netherlands 1411 DC
- IPO Date
- Nov 23, 2022
- CIK
- 0001936258
- Website
- newamsterdampharma.com
- Similar Companies
- Business
- NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a late-stage biopharmaceutical company focused on developing therapies for cardiovascular diseases. The company offers obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels, either as monotherapy or in combination with standard therapies; obicetrapib/ezetimibe, a fixed-dose combination product for patients requiring additional LDL-C lowering; and obicetrapib/padsevonil, an investigational combination targeting both cardiovascular risk factors and potential neurological benefits. These products target patients with dyslipidemia, heterozygous familial hypercholesterolemia (HeFH), and established atherosclerotic cardiovascular disease (ASCVD), addressing unmet needs in lipid management where statins and other treatments fall short. NewAmsterdam operates in the biotechnology sector, with a pipeline centered on oral small-molecule therapies, and serves global markets through clinical trials and regulatory submissions primarily in North America and Europe. Founded in 2019 and headquartered in Naarden, the Netherlands, the company conducts research, development, and commercialization activities across multiple continents, including key operations in the United States via its subsidiary NewAmsterdam Pharma Company USA, Inc. NewAmsterdam maintains strategic collaborations, such as its licensing agreement with Esperion Therapeutics for exclusive rights to obicetrapib in the U.S. and certain other territories, enabling broader market access. The company has no parent entity and focuses exclusively on advancing its obicetrapib franchise without commercialized products as of late 2025. In the past 1-2 years, NewAmsterdam has achieved significant milestones, including positive topline results from the Phase 3 BROADEN, BROOKLYN, and TANDEM trials demonstrating obicetrapib's efficacy in lowering LDL-C by up to 51% as monotherapy and achieving 51% LDL-C reduction in combination with ezetimibe; completion of patient enrollment in the Phase 3 PREVAIL outcomes trial evaluating cardiovascular event reduction; and submission of New Drug Applications (NDAs) to the U.S. FDA and Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for obicetrapib in HeFH and ASCVD patients on top of maximally tolerated lipid-lowering therapies in Q2 2025. Additionally, the company reported full-year 2024 financial results highlighting a cash runway into 2027, initiated a Phase 1 trial for the obicetrapib/padsevonil combination in mid-2025, and expanded its leadership team with key hires in commercial and medical affairs to prepare for potential launches. These developments position NewAmsterdam for regulatory decisions expected in the first half of 2026 and underscore its transition toward commercialization.
Company News
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)